Document:

Exhibit 10.3

 

Inventiva S.A.

A French société anonyme with a share capital of 164,444.77 euros

Registered office: 50 rue de Dijon, 21121 Daix, France

Dijon Trade and Companies Register 537 530 255

 

TERMS AND CONDITIONS OF THE FREE SHARE PLAN (AGA 2018-2)

 

(CSM dated September 30, 2016)

 

ARTICLE 1 - PURPOSE

 

The purpose of the plan (hereafter the “Free Share Plan” or the “Plan”) is to set forth the terms and conditions of the ordinary shares allotted for free (actions attribuées à titre gratuit) (hereafter the “AGA 2018-2” or the “Free Shares”), pursuant to the decisions of the Board of Directors dated January 26, 2018, taken pursuant to the delegation granted by the Combined Shareholders’ Meeting (17th resolution) on September 30, 2016 of Inventiva S.A., a French société anonyme with a share capital of 164,444.77 euros having its registered office 50 rue de Dijon, 21121 Daix, France, registered with the Trade Register of Dijon under number 537 530 255 (the “Company”), allowing their holders (the “Holders”) to subscribe to the Company’s share capital in the conditions set forth by Articles L. 225-197-1 et seq. of the French Commercial Code.

 

This issuance agreement is constituted by the provisions contained in the minutes of the Combined Shareholders’ Meeting dated September 30, 2016 and the minutes of the Board of Directors’ meeting dated January 26, 2018, the provisions of the Plan decided by the Chairman of the Board and the Chief Executive Officer (Président Directeur Général) on January 26, 2018 and the specific provisions contained in the Allotment Letter countersigned by each Holder.

 

The purpose of the Free Share Plan is to allow employees to benefit from the possibility of becoming shareholders of the Company.

 

The objective pursued by the shareholders is to provide certain benefits to Holders who, through their actions, can have a direct and positive influence on the Company and/or its affiliates’ future results and with whom, in a strong mutual trust and for incentive purposes, they wish to share the benefits of the Company’s growth.

 

Upon completion of the Vesting Period referred to in Article 2 below and its adherence to the Free Share Plan that governs it, evidence of the subscription by a Holder of its Free Shares is given by initialing and by counter-signing (i) the Allotment Letter of the Free Shares hand-delivered to each Holder and (ii) a copy of the Free Share Plan.

 

ARTICLE 2 - VESTING PERIOD

 

The final allotment of the Company’s free shares will only occur at the end of a one (1) year vesting period, i.e starting from January 26, 2020 (the “Vesting Period”), except in case of an accelerated vesting decided by the Board of Directors and motivated by a public offer resulting in a change of control of the Company.

 

 

During this Vesting Period:

 

·                  Holders will not be owners of the freely allotted shares and the related rights resulting from this allotment may not be transferred. Notwithstanding the above provision, in case of death of a Holder, its heirs will be entitled to request the allotment of the Free Shares within six (6) months from the death;

 

·                  In case of retirement or disability other than those mentioned in Article L. 225-197-1, I paragraph 5 of the French Commercial Code, Holders will be entitled to request an accelerated vesting of their Free Shares within 6 months from the triggering event;

 

·                  In case of dismissal for personal reason or resignation by the Holder, such Holder shall lose its rights to the Free Shares;

 

·                  In case of an economic dismissal, Holders shall lose their rights to Free Shares unless otherwise decided by the Board of Directors.

 

ARTICLE 3 - HOLDING PERIOD

 

Free Shares will not be assignable during a one (1) year period starting at the end of the Vesting Period (the “Holding Period”), i.e ending on January 26, 2021, other than by inheritance and in the event of an accelerated vesting decided by the Board of Directors and motivated by a public offering resulting in a change of control of the Company.

 

ARTICLE 4 - TERMS AND CONDITIONS OF THE SUBSCRIPTION AND ISSUANCE, OR ACQUISITION, OF THE FREE SHARES

 

Subscription of the Free Shares by a Holder will be received by the Company at its registered office upon delivery by such Holder, no later than March 15, 2018, of a counter-signed copy of the Allotment Letter delivered by the Chairman of the Board and the Chief Executive Officer (Président Directeur Général), acting pursuant to a sub-delegation given by the Board of Directors.

 

The issuance of the Free Shares will occur automatically at the end of the Vesting Period mentioned in Article 2 above, by way of a capital increase of the Company, which will be realized by debiting the unavailable reserve, constituted for this matter.

 

The capital increase will be fully realized by sole virtue of the final allotment of the Free Shares to their Holders, at the end of the Vesting Period mentioned in Article 2 above, the authorization involving, automatically, in favor of the Holders, the waiver by the shareholders of their preferential subscription rights to the ordinary shares that will be issued at the end of the Vesting Period.

 

By way of exemption, the Chairman of the Board and Chief Executive Officer (Président Directeur Général) acting under a sub-delegation given by the Board of Directors, will be able to decide, until the day before the end of the Vesting Period, that the Free Shares will be outstanding shares.

 

ARTICLE 5 - ISSUANCE PRICE OF THE AGA 2018-2

 

The issuance price per Free Share will be equal to their par value as set forth by the by-laws (€0.01 on the date of this Plan).

 

 

ARTICLE 6 - NATURE OF THE AGA 2018-2

 

All of the Free Shares will be ordinary shares.

 

ARTICLE 7 - CONSEQUENCES OF THE SUBSCRIPTION OF THE AGA 2018-2

 

7.1                              A the end of the Vesting Period mentioned in Article 2 above, the subscription of the Free Shares will automatically lead to full and complete consent and adherence from the Holders to any and all of the terms and conditions of the issuance and the allotment set forth in the minutes of the Combined Shareholders’ Meeting dated September 30, 2016, the minutes of the Board of Directors’ meetings dated January 26, 2018, the Free Share Plan and  the Allotment Letter.

 

7.2                              Free Shares will be created with full rights from the first day of the fiscal year during which they will effectively be issued and will give rights to all dividends paid during such fiscal year.

 

7.3                              From the day of creation, such Free Shares will (i) be assimilated to outstanding ordinary shares of the same class; (ii) benefit from the same rights; and (iii) be subject to the same by-laws provisions and shareholders meeting’s resolutions.

 

ARTICLE 8 - PROTECTION OF HOLDERS’ RIGHTS

 

The Company will protect the rights of Holders of Free Shares in the conditions set forth by law and regulation.

 

ARTICLE 9 - CONFIDENTIALITY

 

Each Holder of Free Shares undertakes to respect an obligation of discretion (obligation de discrétion) with respect to the number of Shares freely allotted, in particular regarding the Company’s other employees.

 

ARTICLE 10 - POWERS OF THE CHAIRMAN OF THE BOARD AND CHIEF EXECUTIVE OFFICER (Président Directeur Général)

 

10.1                       In accordance with the decisions of the Combined Shareholders Meeting’s dated September 30, 2016 and the Board of Directors meetings’ dated January 26, 2018, all powers have been granted to the Chairman of the Board and Chief Executive Officer (Président Directeur Général) for the purpose of, in particular:

 

·                  Acknowledging the occurrence of the end of the Vesting Period and the presence on that date of the Holders designated above;

 

·                  Determining whether the AGA 2018-2 will be shares to be issued or outstanding shares, their amount and the Holders concerned;

 

·                  Proceeding with the capital increase resulting from the issuance of Free Shares at the end of the Vesting Period by compensation with the unavailable reserve constituted for this matter;

 

·                  Adjusting, if necessary, during the Vesting Period, the number of shares freely allotted, depending on potential operations on the Company’s share capital in order to preserve the rights of the Holders under the terms that it shall determine;

 

 

·                  Acknowledging the completion of the capital increases up to the number of shares that will effectively be allotted freely to Holders, consequently amending the by-laws, collecting the necessary funds in order to increase the legal reserve up to 10% of the new share capital after each capital increase, and proceeding with all formalities and declarations, requiring all authorizations that would be necessary to the completion of this issuance, entering into any contract in particular to achieve the completion of the considered issuances, taking any action and undertaking any formality useful to the listing and the financial service of the shares issued under this delegation and the exercise of the rights attached to such shares and more generally, doing everything necessary;

 

·                  Ensuring that the Holding Period is complied with by the Holders.

 

10.2                  The Holder irrevocably accepts to comply with decisions and findings of the Chairman of the Board and Chief Executive Officer (Président Directeur Général).

 

ARTICLE 11 - FORCE MAJEURE

 

In the event of force majeure arising independently of the sole will of the Company, Free Shares may be cancelled by the Company with no obligation to indemnify the Holders of the losses arising from such cancellation. For the purpose of the above, in particular, the following are deemed to be events of force majeure: any legal or regulatory change affecting the legal, social or tax treatment of the Free Shares and having financial consequences for the Company that are unknown to this day and any decision or recommendation of a Market Authority requiring the cancellation of the Free Shares.

 

ARTICLE 12 - TAX AND SOCIAL TREATMENT

 

12.1                       Under their responsibility, Holders are invited to seek advice on the tax and social treatment applicable to the Free Shares in their country of tax residence. Each Holder assumes sole responsibility for the payment of all taxes and tax and social security contributions that she or he is subject to by law due to the acquisition and/or the sale of the Free Shares she or he received. In addition, each Holder will be responsible for the payment of any social costs, taxes, tax and social contributions related to Free Shares that would be due by the Company in case of non-compliance by such Holder with the Holding Period mentioned in Article 3 above.

 

12.2                       It is reminded, to the extent necessary, that in order to benefit from the tax regime of transfer capital gains and acquisition profits, Holders will not be able to sell their Free Shares, partially or totally, during the Holding Period mentioned in Article 3 above, otherwise they will bear all and any social and tax consequences.

 

ARTICLE 13 - GOVERNING LAW - JURISDICTION

 

The Free Share Plan is governed by French Law. Any dispute arising from this Plan shall be submitted to the exclusive jurisdiction of the Tribunal de commerce of Dijon.

 

 

Inventiva S.A.

A French société anonyme with a share capital of 222,572.77 euros

Registered office: 50 rue de Dijon, 21121 Daix, France

Dijon Trade and Companies Register 537 530 255

 

TERMS AND CONDITIONS OF THE FREE SHARE PLAN (AGA 2018-3)

 

(CSM dated May 28, 2018)

 

ARTICLE 1 - PURPOSE

 

The purpose of the plan (hereafter the “Free Share Plan” or the “Plan”) is to set forth the terms and conditions of the ordinary shares allotted for free (actions attribuées à titre gratuit) (hereafter the “AGA 2018-3” or the “Free Shares”), pursuant to the decisions of the Board of Directors dated December 14, 2018, taken pursuant to the delegation granted by the Combined Shareholders’ Meeting (26th resolution) on May 28, 2018 of Inventiva S.A., a French société anonyme with a share capital of 222,572.77 euros having its registered office 50 rue de Dijon, 21121 Daix, France, registered with the Trade Register of Dijon under number 537 530 255 (the “Company”), allowing their holders (the “Holders”) to subscribe to the Company’s share capital in the conditions set forth by Articles L. 225-197-1 et seq. of the French Commercial Code.

 

This issuance agreement is constituted by the provisions contained in the minutes of the Combined Shareholders’ Meeting dated May 28, 2018 and the minutes of the Board of Directors’ meeting dated December 14, 2018, the provisions of this Plan and the specific provisions contained in the Allotment Letter countersigned by each Holder.

 

The purpose of the Free Share Plan is to allow employees to benefit from the possibility of becoming shareholders of the Company.

 

The objective pursued by the shareholders is to provide certain benefits to Holders who, through their actions, can have a direct and positive influence on the Company and/or its affiliates’ future results and with whom, in a strong mutual trust and for incentive purposes, they wish to share the benefits of the Company’s growth.

 

Upon completion of the Vesting Period referred to in Article 2 below and its adherence to the Free Share Plan that governs it, evidence of the subscription by a Holder of its Free Shares is given by initialing and by counter-signing (i) the Allotment Letter of the Free Shares hand-delivered to the interested party and (ii) a copy of the Free Share Plan.

 

ARTICLE 2 - VESTING PERIOD

 

The final allotment of the Company’s free shares will only occur at the end of a two-year vesting period, i.e starting from December 14, 2020 (the “Vesting Period”), except in case of an accelerated vesting

 

 

decided by the Board of Directors and motivated by a public offer resulting in a change of control of the Company.

 

During this Vesting Period:

 

·                  Holders will not be owners of the freely allotted shares and the related rights resulting from this allotment may not be transferred. Notwithstanding the above provision, in case of death of a Holder, its heirs will be entitled to request the allotment of the Free Shares within six (6) months from the death;

 

·                  In case of dismissal for personal reason or resignation by the Holder, such Holder shall lose its rights to the Free Shares;

 

·                  In case of an economic dismissal, Holders shall lose their rights to Free Shares unless otherwise decided by the Board of Directors.

 

ARTICLE 3 - HOLDING PERIOD

 

Free Shares will not be assignable during a one (1) year period starting at the end of the Vesting Period (the “Holding Period”), i.e ending on December 14, 2021, other than by inheritance and in the event of an accelerated vesting decided by the Board of Directors and motivated by a public offering resulting in a change of control of the Company.

 

ARTICLE 4 - TERMS AND CONDITIONS OF THE SUBSCRIPTION AND ISSUANCE, OR ACQUISITION, OF THE FREE SHARES

 

Subscription of the Free Shares by a Holder will be received by the Company at its registered office upon delivery by such Holder, of a counter-signed copy of the Allotment Letter delivered by the Chairman of the Board and the Chief Executive Officer (Président Directeur Général), acting pursuant to a sub-delegation given by the Board of Directors.

 

The issuance of the Free Shares will occur automatically at the end of the Vesting Period mentioned in Article 2 above, by way of a capital increase of the Company, which will be realized by debiting the carry forward account (poste de report à nouveau). The capital increase will be fully realized by sole virtue of the final allotment of the Free Shares to their Holders, at the end of the Vesting Period mentioned in Article 2 above, the authorization involving, automatically, in favor of the Holders, the waiver by the shareholders of their preferential subscription rights to the ordinary shares that will be issued at the end of the Vesting Period. By way of exemption, the Chairman of the Board and Chief Executive Officer (Président Directeur Général) acting under a sub-delegation given by the Board of Directors, will be able to decide, until the day before the end of the Vesting Period, that the Free Shares will be outstanding shares.

 

ARTICLE 5 - ISSUANCE PRICE OF THE AGA 2018-3

 

The issuance price per Free Share will be equal to their par value as set forth by the by-laws (€0.01 on the date of this Plan).

 

ARTICLE 6 - NATURE OF THE AGA 2018-3

 

All of the Free Shares will be ordinary shares.

 

 

ARTICLE 7 - CONSEQUENCES OF THE SUBSCRIPTION OF THE AGA 2018-2

 

7.1                              A the end of the Vesting Period mentioned in Article 2 above, the subscription of the Free Shares will automatically lead to full and complete consent and adherence from the Holders to any and all of the terms and conditions of the issuance and the allotment set forth in the minutes of the Combined Shareholders’ Meeting dated May 28, 2018, the minutes of the Board of Directors’ meetings dated December 14, 2018, the Free Share Plan and  the Allotment Letter.

 

7.2                              Free Shares will be created with full rights from the first day of the fiscal year during which they will effectively be issued and will give rights to all dividends paid during such fiscal year.

 

7.3                              From the day of creation, such Free Shares will (i) be assimilated to outstanding ordinary shares of the same class; (ii) benefit from the same rights; and (iii) be subject to the same by-laws provisions and shareholders meeting’s resolutions.

 

ARTICLE 8 - PROTECTION OF HOLDERS’ RIGHTS

 

The Company will protect the rights of Holders of Free Shares in the conditions set forth by law and regulation.

 

ARTICLE 9 - CONFIDENTIALITY

 

Each Holder of Free Shares undertakes to respect an obligation of discretion (obligation de discrétion) with respect to the number of Shares freely allotted, in particular regarding the Company’s other employees.

 

ARTICLE 10 - POWERS OF THE CHAIRMAN OF THE BOARD AND CHIEF EXECUTIVE OFFICER (Président Directeur Général)

 

10.1                       In accordance with the decisions of the Combined Shareholders Meeting’s dated May 28, 2018 and the Board of Directors meeting’s dated December 14, 2018, all powers have been granted to the Chairman of the Board and Chief Executive Officer (Président Directeur Général) for the purpose of, in particular:

 

·                  Acknowledging the occurrence of the end of the Vesting Period and the presence on that date of the Holders designated above;

 

·                  Determining whether the AGA 2018-3 will be shares to be issued or outstanding shares, their amount and the Holders concerned;

 

·                  Proceeding with the capital increase resulting from the issuance of Free Shares at the end of the Vesting Period by debiting the carry forward account (poste de report à nouveau);

 

·                  Adjusting, if necessary, during the Vesting Period, the number of shares freely allotted, depending on potential operations on the Company’s share capital in order to preserve the rights of the Holders under the terms that it shall determine;

 

·                  Acknowledging the completion of the capital increases up to the number of shares that will effectively be allotted freely to Holders, consequently amending the by-laws, collecting the necessary funds in order to increase the legal reserve up to 10% of the new share capital after each capital increase, and proceeding with all formalities and declarations, requiring all

 

 

authorizations that would be necessary to the completion of this issuance, entering into any contract in particular to achieve the completion of the considered issuances, taking any action and undertaking any formality useful to the listing and the financial service of the shares issued under this delegation and the exercise of the rights attached to such shares and more generally, doing everything necessary;

 

·                  Ensuring that the Holding Period is complied with by the Holders.

 

10.2                       The Holder irrevocably accepts to comply with decisions and findings of the Chairman of the Board and Chief Executive Officer (Président Directeur Général).

 

ARTICLE 11 - FORCE MAJEURE

 

In the event of force majeure arising independently of the sole will of the Company, Free Shares may be cancelled by the Company with no obligation to indemnify the Holders of the losses arising from such cancellation. For the purpose of the above, in particular, the following are deemed to be events of force majeure: any legal or regulatory change affecting the legal, social or tax treatment of the Free Shares and having financial consequences for the Company that are unknown to this day and any decision or recommendation of a Market Authority requiring the cancellation of the Free Shares.

 

ARTICLE 12 - TAX AND SOCIAL TREATMENT

 

12.1                       Under their responsibility, Holders are invited to seek advice on the tax and social treatment applicable to the Free Shares in their country of tax residence. Each Holder assumes sole responsibility for the payment of all taxes and tax and social security contributions that she or he is subject to by law due to the acquisition and/or the sale of the Free Shares she or he received. In addition, each Holder will be responsible for the payment of any social costs, taxes, tax and social contributions related to Free Shares that would be due by the Company in case of non-compliance by such Holder with the Holding Period mentioned in Article 3 above.

 

12.2                       It is reminded, to the extent necessary, that in order to benefit from the tax regime of transfer capital gains, Holders will not be able to sell their Free Shares, partially or totally, during the Holding Period mentioned in Article 3 above, otherwise they will bear all and any social and tax consequences.

 

ARTICLE 13 - GOVERNING LAW - JURISDICTION

 

The Free Share Plan is governed by French Law. Any dispute arising from this Plan shall be submitted to the exclusive jurisdiction of the Tribunal de commerce of Dijon.Exhibit 4.1

    

     

    

    [FORM OF SERIES [A] [B] WARRANT]

     

    NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
      AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS.  THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
      OR (B) AN OPINION OF COUNSEL SELECTED BY THE HOLDER, IN A FORM REASONABLY SATISFACTORY TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. 
      NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

     

    OCUPHIRE PHARMA, INC.

     

    Series [A] [B] Warrant To Purchase Common Stock

     

    	
            Warrant No.:

          	

          	 

    	
            Number of Shares of Common Stock:

          	

          	 

    	
            Date of Issuance:

          	
            [●], 20201 (“Issuance Date”)

          

     

    

    Ocuphire Pharma, Inc., a Delaware corporation formerly known as Rexahn Pharmaceuticals, Inc. (the “Company”), hereby certifies that, for good and valuable
      consideration, the receipt and sufficiency of which are hereby acknowledged, [HOLDER], the registered holder hereof or its permitted assigns (the “Holder”), is entitled, subject to the terms set forth below, to
      purchase from the Company, at the Exercise Price (as defined below) then in effect, at any time or times on or after the date hereof, but not after 11:59 p.m., New York time, on the Expiration Date, (as defined below), [INSERT IN SERIES A WARRANT:___________________ (__________)2 fully paid nonassessable shares of Common Stock] [INSERT IN SERIES B WARRANT: a number of fully paid nonassessable shares of Common Stock equal to the Maximum Eligibility Number], subject to adjustment as provided herein (the “Warrant Shares”).  Except as otherwise defined herein, capitalized terms in this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock
      issued in exchange, transfer or replacement hereof, this “Warrant”), shall have the meanings set forth in Section 18.  This Warrant is one of the [INSERT IN SERIES A WARRANT: Series

      A] [INSERT IN SERIES B WARRANT: Series B] Warrants to purchase Common Stock (the “SPA Warrants”) issued pursuant to Section 1 of that certain Securities Purchase
      Agreement, dated as of June [•], 2020 (the “Subscription Date”), by and among the Company, Ocuphire Pharma, Inc., a Delaware corporation (“Ocuphire Private Company”), and
      the investors (the “Buyers”) referred to therein (as may be amended, amended and restated, supplemented or otherwise modified from time to time in accordance with its terms, the “Securities Purchase Agreement”).  Capitalized terms used herein and not otherwise defined shall have the definitions ascribed to such terms in the Securities Purchase Agreement.

     

    
      
 

  

  1 Insert the Warrant Closing Date (as defined in the Securities Purchase Agreement).
    2 Insert 100% of the sum of (i) the number of Exchange Shares issued in exchange for the number of Initial Common Shares (as defined in
      the Securities Purchase Agreement) purchased by the Holder pursuant to the Securities Purchase Agreement, (ii) the number of Exchange Shares issued in exchange of the number of Additional Common Shares (as defined in the Securities Purchase
      Agreement) delivered or deliverable to the Holder pursuant to the Securities Purchase Agreement without giving effect to any limitation on delivery to the Holder pursuant to Section 1(c)(iv) of the Securities Purchase Agreement and (iii) the Initial
      Maximum Eligibility Number (as defined in the Series B Warrants).

     

    
      
        

    

    1.        EXERCISE OF WARRANT.

     

    (a)  Mechanics of Exercise.  Subject to the terms and conditions hereof (including, without limitation, the limitations set forth in Section 1(f)), this Warrant may be exercised by the
      Holder at any time or times on or after the Issuance Date, in whole or in part, by (i) delivery of a written notice, in the form attached hereto as Exhibit A (the “Exercise Notice”), of the Holder’s
      election to exercise this Warrant and (ii) (A) payment to the Company of an amount equal to the applicable Exercise Price multiplied by the number of Warrant Shares as to which this Warrant is being exercised (the “Aggregate

        Exercise Price”) in cash by wire transfer of immediately available funds or (B) [INSERT IN SERIES A WARRANT: if the provisions of Section 1(d) are applicable,]
      by notifying the Company that this Warrant is being exercised pursuant to a Cashless Exercise (as defined in Section 1(d)).  The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder, nor shall any
      ink-original signature or medallion guarantee (or other type of guarantee or notarization) with respect to any Exercise Notice be required.  Execution and delivery of the Exercise Notice with respect to less than all of the Warrant Shares shall have
      the same effect as cancellation of the original Warrant and issuance of a new Warrant evidencing the right to purchase the remaining number of Warrant Shares.  On or before the first (1st) Trading Day following the date on which the Holder has delivered the applicable Exercise Notice to the Company, the Company shall transmit by facsimile or electronic mail an acknowledgment of confirmation of receipt of the
      Exercise Notice to the Holder and the Company’s transfer agent (the “Transfer Agent”).  On or before the applicable Share Delivery Date, the Company shall (X) provided that the Transfer Agent is participating
      in The Depository Trust Company (“DTC”) Fast Automated Securities Transfer Program and (A) the applicable Warrant Shares are subject to an effective resale registration statement in favor of the Holder or (B)
      if exercised via Cashless Exercise, at a time when Rule 144 would be available for immediate resale of the applicable Warrant Shares by the Holder, credit such aggregate number of Warrant Shares to which the Holder is entitled pursuant to such
      exercise to the Holder’s or its designee’s balance account with DTC through its Deposit / Withdrawal At Custodian system, or (Y) if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program or (A) the applicable
      Warrant Shares are not subject to an effective resale registration statement in favor of the Holder and (B) if exercised via Cashless Exercise, at a time when Rule 144 would not be available for immediate resale of the applicable Warrant Shares by
      the Holder, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the
      Holder is entitled pursuant to such exercise.  The Company shall be responsible for all fees and expenses of the Transfer Agent and all fees and expenses with respect to the issuance of Warrant Shares via DTC, if any, including, without limitation,
      for same day processing.  Upon delivery of the Exercise Notice, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the
      date such Warrant Shares are credited to the Holder’s DTC account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be.  If this Warrant is submitted in connection with any exercise pursuant to this Section
      1(a) and the number of Warrant Shares represented by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired upon an exercise, then the Company shall as soon as practicable and in no event later than two (2)
      Trading Days after any exercise and at its own expense, issue a new Warrant (in accordance with Section 7(d)) representing the right to purchase the number of Warrant Shares issuable immediately prior to such exercise under this Warrant, less the
      number of Warrant Shares with respect to which this Warrant is exercised.  No fractional Warrant Shares are to be issued upon the exercise of this Warrant, but rather the number of Warrant Shares to be issued shall be rounded up to the nearest whole
      number.  The Company shall pay any and all taxes which may be payable with respect to the issuance and delivery of Warrant Shares upon exercise of this Warrant.  The Company’s obligations to issue and deliver Warrant Shares in accordance with the
      terms and subject to the conditions hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any
      Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination. While any SPA Warrants remain outstanding, the Company shall use a transfer agent that
        participates in the DTC Fast Automated Securities Transfer Program. [INSERT IN SERIES B WARRANT: NOTWITHSTANDING ANY PROVISION OF THIS WARRANT TO THE CONTRARY, NO MORE
        THAN THE MAXIMUM ELIGIBILITY NUMBER OF WARRANT SHARES SHALL BE EXERCISABLE IN THE AGGREGATE HEREUNDER.]  For the avoidance of doubt, without limiting any rights of a Holder to receive cash payments pursuant to Section 1(c) below, the Company
      shall not be required to cash settle the exercise of this Warrant if an effective resale registration statement is not in place at the time of exercise.

     

    
      
        

    

    (b)  Exercise Price.  For purposes of this Warrant, “Exercise Price” means $[•]3 per share, subject to adjustment as provided herein.

     

    (c)  Company’s Failure to Timely Deliver Securities.  If the Company shall fail for any reason or for no reason to issue to the Holder on or prior to the applicable Share Delivery Date
      either (I) if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, a certificate for the number of shares of Common Stock to which the Holder is entitled and register such shares of Common Stock on the
      Company’s share register or if the Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program, to credit the Holder’s balance account with DTC, for such number of shares of Common Stock to which the Holder is entitled upon
      the Holder’s exercise of this Warrant or (II) if the Registration Statement covering the resale of the Warrant Shares that are the subject of the Exercise Notice (the “Unavailable Warrant Shares”) is not
      available for the resale of such Unavailable Warrant Shares and the Company fails to promptly, but in no event later than as is required pursuant to the Registration Rights Agreement (x) so notify the Holder and (y) deliver the Warrant Shares
      electronically without any restrictive legend by crediting such aggregate number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the Holder’s or its designee’s balance account with DTC through its Deposit / Withdrawal
      At Custodian system (the event described in the immediately foregoing clause (II) is hereinafter referred as a “Notice Failure” and together with the event described in clause (I) above, an “Exercise Failure”), then, in addition to all other remedies available to the Holder, (X) the Company shall pay in cash to the Holder on each day after the applicable Share Delivery Date and during such Exercise
      Failure an amount equal to 1.5% of the product of (A) the number of shares of Common Stock not issued to the Holder on or prior to the applicable Share Delivery Date and to which the Holder is entitled, and (B) any trading price of the Common Stock
      selected by the Holder in writing as in effect at any time during the period beginning on the applicable date of delivery of the applicable Exercise Notice and ending on the applicable Share Delivery Date, and (Y) the Holder, upon written notice to
      the Company, may void its Exercise Notice with respect to, and retain or have returned, as the case may be, any portion of this Warrant that has not been exercised pursuant to such Exercise Notice; provided that the voiding of an Exercise Notice
      shall not affect the Company’s obligations to make any payments which have accrued prior to the date of such notice pursuant to this Section 1(c) or otherwise.  In addition to the foregoing, if on or prior to the applicable Share Delivery Date either
      (I) if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, the Company shall fail to issue and deliver a certificate to the Holder and register such shares of Common Stock on the Company’s share register or,
      if the Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program, credit the Holder’s balance account with DTC for the number of shares of Common Stock to which the Holder is entitled upon the Holder’s exercise hereunder
      or pursuant to the Company’s obligation pursuant to clause (ii) below or (II) a Notice Failure occurs, and if on or after such Trading Day the Holder purchases (in an open market transaction or otherwise) shares of Common Stock relating to the
      applicable Exercise Failure (a “Buy-In”), then the Company shall, within three (3) Trading Days after the Holder’s request and in the Holder’s discretion, either (i) pay cash to the Holder in an amount equal to
      the Holder’s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (the “Buy-In Price”), at which point the Company’s
      obligation to deliver such certificate (and to issue such shares of Common Stock) or credit the Holder’s balance account with DTC for such shares of Common Stock shall terminate, or (ii) promptly honor its obligation to deliver to the Holder a
      certificate or certificates representing such shares of Common Stock or credit the Holder’s balance account with DTC, as applicable, and pay cash to the Holder in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such
      number of shares of Common Stock, times (B) any trading price of the Common Stock selected by the Holder in writing as in effect at any time during the period beginning on the date of delivery of the applicable Exercise Notice and ending on the
      applicable Share Delivery Date.  Nothing herein shall limit the Holder’s right to pursue any other remedies available to it hereunder, at law or in equity, including, without limitation, a decree of specific performance and/or injunctive relief with
      respect to the Company’s failure to timely deliver certificates representing shares of Common Stock (or to electronically deliver such shares of Common Stock) upon the exercise of this Warrant as required pursuant to the terms hereof.

     

    
      
 

    3 [INSERT IN SERIES A WARRANT: Insert 120% of the Final Per Share Price (as defined in the
      Securities Purchase Agreement), rounded to four decimal places.]

     

    [INSERT IN SERIES B WARRANT: Insert 0.0001.]

     

    
      
        

    

    (d)  Cashless Exercise.  Notwithstanding anything contained herein to the contrary, [INSERT IN SERIES A WARRANT: if

      the Registration Statement covering the resale of the Unavailable Warrant Shares is not available for the resale of such Unavailable Warrant Shares,] the Holder may, in its sole discretion, exercise this
      Warrant in whole or in part and, in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the Aggregate Exercise Price, elect instead to receive upon such exercise the “Net Number” of shares
      of Common Stock determined according to the following formula (a “Cashless Exercise”):

     

    Net Number = (A x B) - (A x C)

    B

     

    For purposes of the foregoing formula:

     

    A= the total number of shares with respect to which this Warrant is then being exercised.

     

    B= as applicable: (i) the Weighted Average Price of the Common Stock on the Trading Day immediately preceding the date of the applicable Exercise Notice if
      such Exercise Notice is (1) both executed and delivered pursuant to Section 1(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 1(a) hereof on a Trading Day prior to the opening of “regular trading
      hours” (as defined in Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the Weighted Average Price of the Common Stock on the Trading Day immediately
      preceding the date of the applicable Exercise Notice or (z) the Bid Price of the Common Stock on the principal Eligible Market for the Common Stock as reported by Bloomberg as of the time of the Holder’s execution of the applicable Exercise Notice if
      such Exercise Notice is executed during “regular trading hours” on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours” on a Trading Day) pursuant to Section 1(a)
      hereof or (iii) the Weighted Average Price of the Common Stock on the date of the applicable Exercise Notice if the date of such Exercise Notice is a Trading Day and such Exercise Notice is both executed and delivered pursuant to Section 1(a) hereof
      after the close of “regular trading hours” on such Trading Day.

     

    C= the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise.

     

    
      
        

    

    If shares of Common Stock are issued pursuant to this Section 1(d), the Company hereby acknowledges and agrees that the Warrant Shares issued in a Cashless Exercise shall be deemed to have been acquired by the Holder,
      and the holding period for the Warrant Shares for purposes of Rule 144(d), shall be deemed to have commenced, on the date this Warrant was originally issued pursuant to the Securities Purchase Agreement. The Company agrees not to take any position
      contrary to this Section 1(d).

     

    (e)  Disputes.  In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall promptly issue to the Holder the
      number of Warrant Shares that are not disputed and resolve such dispute in accordance with Section 12.

     

    (f)  Beneficial Ownership Limitation on Exercises.  Notwithstanding anything to the contrary contained herein, the Company shall not effect the exercise of any portion of this Warrant, and
      the Holder shall not have the right to exercise any portion of this Warrant, pursuant to the terms and conditions of this Warrant and any such exercise shall be null and void and treated as if never made, to the extent that after giving effect to
      such exercise, the Holder together with the other Attribution Parties collectively would beneficially own in excess of [4.99] [9.99]%4 (the “Maximum Percentage”) of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.  For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by
      the Holder and the other Attribution Parties shall include the number of shares of Common Stock held by the Holder and all other Attribution Parties plus the number of shares of Common Stock issuable upon exercise of this Warrant with respect to
      which the determination of such sentence is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (A) exercise of the remaining, unexercised portion of this Warrant beneficially owned by the Holder or any of
      the other Attribution Parties and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company (including, without limitation, any convertible notes or convertible preferred stock or warrants, including
      the [INSERT IN SERIES A WARRANT: Series B] [INSERT IN SERIES B WARRANT: Series A] Warrants) beneficially owned by the Holder or any other Attribution Party subject to a
      limitation on conversion or exercise analogous to the limitation contained in this Section 1(f).  For purposes of this Section 1(f), beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as
      amended (the “1934 Act”).  For purposes of this Warrant, in determining the number of outstanding shares of Common Stock the Holder may acquire upon the exercise of this Warrant without exceeding the Maximum
      Percentage, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current Report on Form 8-K or other public filing with the
      Securities and Exchange Commission (the “SEC”), as the case may be, (y) a more recent public announcement by the Company or (3) any other written notice by the Company or the Transfer Agent setting forth the
      number of shares of Common Stock outstanding (the “Reported Outstanding Share Number”).  If the Company receives an Exercise Notice from the Holder at a time when the actual number of outstanding shares of
      Common Stock is less than the Reported Outstanding Share Number, the Company shall (i) promptly notify the Holder in writing of the number of shares of Common Stock then outstanding and, to the extent that such Exercise Notice would otherwise cause
      the Holder’s beneficial ownership, as determined pursuant to this Section 1(f), to exceed the Maximum Percentage, the Holder must notify the Company of a reduced number of Warrant Shares to be purchased pursuant to such Exercise Notice (the number of
      shares by which such purchase is reduced, the “Reduction Shares”) and (ii) as soon as reasonably practicable, the Company shall return to the Holder any exercise price paid by the Holder for the Reduction
      Shares.  For any reason at any time, upon the written or oral request of the Holder, the Company shall within one (1) Trading Day confirm in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding.  In any
      case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder and any other Attribution Party since the date as of
      which the Reported Outstanding Share Number was reported.  In the event that the issuance of shares of Common Stock to the Holder upon exercise of this Warrant results in the Holder and the other Attribution Parties being deemed to beneficially own,
      in the aggregate, more than the Maximum Percentage of the number of outstanding shares of Common Stock (as determined under Section 13(d) of the 1934 Act), the number of shares so issued by which the Holder’s and the other Attribution Parties’
      aggregate beneficial ownership exceeds the Maximum Percentage (the “Excess Shares”) shall be deemed null and void and shall be cancelled ab initio and any portion of this Warrant so exercised shall be
      reinstated, and the Holder shall not have the power to vote or to transfer the Excess Shares.  As soon as reasonably practicable after the issuance of the Excess Shares has been deemed null and void, the Company shall return to the Holder the
      exercise price paid by the Holder for the Excess Shares.  Upon delivery of a written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage not in excess of 9.99% as specified in
      such notice; provided that (i) any such increase in the Maximum Percentage will not be effective until the sixty-first (61st) day after such notice is delivered to the
      Company and (ii) any such increase or decrease will apply only to the Holder and the other Attribution Parties and not to any other holder of SPA Warrants that is not an Attribution Party of the Holder.  For purposes of clarity, the shares of Common
      Stock issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the 1934 Act.  No prior inability to exercise this Warrant pursuant to this paragraph shall have any effect on the applicability of the provisions of this paragraph with respect to any subsequent determination
      of exercisability.  The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 1(f) to the extent necessary to correct this paragraph or any portion of this
      paragraph which may be defective or inconsistent with the intended beneficial ownership limitation contained in this Section 1(f) or to make changes or supplements necessary or desirable to properly give effect to such limitation.  The limitation
      contained in this paragraph may not be waived and shall apply to a successor holder of this Warrant.  For the avoidance of doubt, without limiting any rights of a Holder to receive cash payments pursuant to Section 1(c) below, in no event shall the
      Company be required to cash settle any Excess Shares.

     

    

    4 Insert Maximum Percentage as indicated on the Buyer’s signature page attached to the Securities Purchase Agreement.

     

    
      
        

    

    (g)  Insufficient Authorized Shares.  If at any time while this Warrant remains outstanding the Company does not have a sufficient number of authorized and unreserved shares of Common Stock
      to satisfy its obligation to reserve for issuance upon exercise of this Warrant at least a number of shares of Common Stock equal to: (i) until the Reservation Date, [INSERT IN SERIES A WARRANT: 135% of the
      number of Warrant Shares issued and issuable pursuant to the SPA Warrants determined in accordance with Section 2(d) assuming a Reset Price equal to the Reset Floor Price without giving effect to any limitation on exercise set forth therein] [INSERT IN SERIES B WARRANT: the number of Warrant Shares issued and issuable pursuant to the SPA Warrants assuming that the Maximum Eligibility Number is determined based on a Reset Price equal to the Reset Floor
      Price without giving effect to any limitation on exercise set forth therein] and (ii) thereafter, [INSERT IN SERIES A WARRANT: 135%] [INSERT IN SERIES B WARRANT: 100%] of
      the maximum number of shares of Common Stock as shall from time to time be necessary to effect the exercise of all of this Warrant then outstanding without regard to any limitation on exercise included herein (the foregoing clauses (i) and (ii), as
      applicable, the “Required Reserve Amount” and the failure to have such sufficient number of authorized and unreserved shares of Common Stock, an “Authorized Share Failure”),

      then the Company shall immediately take all action necessary to increase the Company’s authorized shares of Common Stock to an amount sufficient to allow the Company to reserve the Required Reserve Amount for this Warrant then outstanding.  Without
      limiting the generality of the foregoing sentence, as soon as practicable after the date of the occurrence of an Authorized Share Failure, but in no event later than sixty (60) days after the occurrence of such Authorized Share Failure, the Company
      shall hold a meeting of its stockholders for the approval of an increase in the number of authorized shares of Common Stock.  In connection with such meeting, the Company shall provide each stockholder with a proxy statement and shall use its best
      efforts to solicit its stockholders’ approval of such increase in authorized shares of Common Stock and to cause its board of directors to recommend to the stockholders that they approve such proposal.  Notwithstanding the foregoing, if any such time
      of an Authorized Share Failure, the Company is able to obtain the written consent of a majority of the shares of its issued and outstanding shares of Common Stock to approve the increase in the number of authorized shares of Common Stock, the Company
      may satisfy this obligation by obtaining such consent and submitting for filing with the SEC an Information Statement on Schedule 14C.  In the event that upon any exercise of this Warrant, the Company does not have sufficient authorized shares to
      deliver in satisfaction of such exercise, then unless the Holder elects to void such attempted exercise, the Holder may require the Company to pay to the Holder within three (3) Trading Days of the applicable exercise, cash in an amount equal to the
      product of (i) the number of Warrant Shares that the Company is unable to deliver pursuant to this Section 1(g) and (ii) the highest Weighted Average Price during the period beginning on the date of such attempted exercise and the date that the
      Company makes the applicable cash payment.

     

    
      
        

    

    2.    ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES.  The Exercise
      Price and the number of Warrant Shares shall be adjusted from time to time as follows:

     

    (a)  [INSERT IN SERIES B WARRANT: Intentionally omitted.] [INSERT IN SERIES A WARRANT: Adjustment Upon Issuance
        of Shares of Common Stock.  If and whenever on or after the Subscription Date to and including the second (2nd) anniversary of the date all Registrable Securities
      (without regard to any Cutback Shares (as defined in the Registration Rights Agreement)) are registered for resale pursuant to one or more Registration Statement(s), the Company publicly announces, issues or sells, enters into a definitive, binding
      agreement pursuant to which the Company is required to issue or sell or, in accordance with clauses (i) or (ii) of this Section 2(a), is deemed to have issued or sold, any shares of Common Stock owned or held by or for the account of the Company, but
      excluding shares of Common Stock deemed to have been issued or sold by the Company in connection with any Excluded Securities) for a consideration per share (the “New Issuance Price”) less than a price (the “Applicable Price”) equal to the Exercise Price in effect immediately prior to such public announcement, issue or sale or deemed issuance or sale or entry into such a definitive, binding agreement (the foregoing a “Dilutive Issuance”), then immediately after such Dilutive Issuance, the Exercise Price then in effect shall be reduced to an amount equal to the New Issuance Price.  Upon each such adjustment of the Exercise Price
      hereunder, the number of Warrant Shares issuable immediately prior to such Dilutive Issuance shall be adjusted to the number of shares of Common Stock determined by multiplying the Exercise Price then in effect immediately prior to such adjustment by
      the number of Warrant Shares acquirable upon exercise of this Warrant immediately prior to such adjustment and dividing the product thereof by the Exercise Price resulting from such adjustment.  For purposes of determining the adjusted Exercise Price
      under this Section 2(a), the following shall be applicable (in each case, rounded to four decimal places):

     

    (i)          Issuance of Options.  If the Company in any manner grants or sells or enters into a definitive, binding agreement pursuant to which the Company is required to
      grant or sell, or the Company publicly announces the issuance or sale of, any Options and the lowest price per share for which one share of Common Stock is issuable upon the exercise of any such Option or upon conversion, exercise or exchange of any
      Convertible Securities issuable upon exercise of any such Option is less than the Applicable Price, then such share of Common Stock shall be deemed to be outstanding and to have been issued and sold by the Company at the time of the granting or sale
      of such Option for such price per share.  For purposes of this Section 2(a)(i), the “lowest price per share for which one share of Common Stock is issuable upon the exercise of any such Option or upon conversion, exercise or exchange of any
      Convertible Securities issuable upon exercise of any such Option” shall be equal to the sum of the lowest amounts of consideration (if any) received or receivable by the Company with respect to any one share of Common Stock upon the granting or sale
      of the Option, upon exercise of the Option and upon conversion, exercise or exchange of any Convertible Security issuable upon exercise of such Option less any consideration paid or payable by the Company with respect to such one share of Common
      Stock upon the granting or sale of such Option, upon exercise of such Option and upon conversion exercise or exchange of any Convertible Security issuable upon exercise of such Option.  No further adjustment of the Exercise Price or number of Warrant
      Shares shall be made upon the actual issuance of such shares of Common Stock or of such Convertible Securities upon the exercise of such Options or upon the actual issuance of such shares of Common Stock upon conversion, exercise or exchange of such
      Convertible Securities.

     

    
      
        

    

    (ii)        Issuance of Convertible Securities.  If the Company in any manner issues or sells, or enters into a definitive, binding agreement pursuant to which the Company
      is required to grant or sell or the Company publicly announces the issuance or sale of, any Convertible Securities and the lowest price per share for which one share of Common Stock is issuable upon the conversion, exercise or exchange thereof is
      less than the Applicable Price, then such share of Common Stock shall be deemed to be outstanding and to have been issued and sold by the Company at the time of the issuance or sale of such Convertible Securities for such price per share.  For the
      purposes of this Section 2(a)(ii), the “lowest price per share for which one share of Common Stock is issuable upon the conversion, exercise or exchange thereof” shall be equal to the sum of the lowest amounts of consideration (if any) received or
      receivable by the Company with respect to any one share of Common Stock upon the issuance or sale of the Convertible Security and upon conversion, exercise or exchange of such Convertible Security less any consideration paid or payable by the Company
      with respect to such one share of Common Stock upon the issuance or sale of such Convertible Security and upon conversion, exercise or exchange of such Convertible Security.  No further adjustment of the Exercise Price or number of Warrant Shares
      shall be made upon the actual issuance of such shares of Common Stock upon conversion, exercise or exchange of such Convertible Securities, and if any such issue or sale of such Convertible Securities is made upon exercise of any Options for which
      adjustment of this Warrant has been or is to be made pursuant to other provisions of this Section 2(a), no further adjustment of the Exercise Price or number of Warrant Shares shall be made by reason of such issue or sale.

     

    (iii)       Change in Option Price or Rate of Conversion.  If the purchase price provided for in any Options, the additional consideration, if any, payable upon the issue,
      conversion, exercise or exchange of any Convertible Securities, or the rate at which any Convertible Securities are convertible into or exercisable or exchangeable for shares of Common Stock increases or decreases at any time, the Exercise Price and
      the number of Warrant Shares in effect at the time of such increase or decrease shall be adjusted to the Exercise Price and the number of Warrant Shares, which would have been in effect at such time had such Options or Convertible Securities provided
      for such increased or decreased purchase price, additional consideration or increased or decreased conversion rate, as the case may be, at the time initially granted, issued or sold.  For purposes of this Section 2(a)(iii), if the terms of any Option
      or Convertible Security that was outstanding as of the Subscription Date are increased or decreased in the manner described in the immediately preceding sentence, then such Option or Convertible Security and the shares of Common Stock deemed issuable
      upon exercise, conversion or exchange thereof shall be deemed to have been issued as of the date of such increase or decrease.  No adjustment pursuant to this Section 2(a) shall be made if such adjustment would result in an increase of the Exercise
      Price then in effect or a decrease in the number of Warrant Shares.

     

    
      
        

    

    (iv)        Calculation of Consideration Received.  If any Option and/or Convertible Security and/or Adjustment Right is issued in connection with the issuance or sale or
      deemed issuance or sale of any other securities of the Company (as determined by the Holder, the “Primary Security”, and such Option and/or Convertible Security and/or Adjustment Right, the “Secondary Securities”), together comprising one integrated transaction, (or one or more transactions if such issuances or sales or deemed issuances or sales of securities of the Company either (A) have at least one
      investor or purchaser in common, (B) are consummated in reasonable proximity to each other and/or (C) are consummated under the same plan of financing) the aggregate consideration per share of Common Stock with respect to such Primary Security shall
      be deemed to be equal to the difference of (x) the lowest price per share for which one share of Common Stock was issued (or was deemed to be issued pursuant to Section 2(a)(i) or Section 2(a)(ii), as applicable) in such integrated transaction solely
      with respect to such Primary Security, minus (y) with respect to such Secondary Securities, the sum of (I) the Black Scholes Consideration Value of each such Option, if any, (II) the fair market value (as determined by the Holder in good faith) or
      the Black Scholes Consideration Value, as applicable, of such Adjustment Right, if any, and (III) the fair market value (as determined by the Holder) of such Convertible Security, if any, in each case, as determined on a per share basis in accordance
      with this Section 2(a)(iv). If any shares of Common Stock, Options or Convertible Securities are issued or sold or deemed to have been issued or sold for cash, the consideration received therefor (for the purpose of determining the consideration paid
      for such Common Stock, Option or Convertible Security, but not for the purpose of the calculation of the Black Scholes Consideration Value) will be deemed to be the net amount of consideration received by the Company therefor. If any shares of Common
      Stock, Options or Convertible Securities are issued or sold for a consideration other than cash, the amount of such consideration received by the Company (for the purpose of determining the consideration paid for such Common Stock, Option or
      Convertible Security, but not for the purpose of the calculation of the Black Scholes Consideration Value) will be the fair value of such consideration, except where such consideration consists of publicly traded securities, in which case the amount
      of consideration received by the Company for such securities will be the arithmetic average of the Weighted Average Prices of such security for each of the five (5) Trading Days immediately preceding the date of receipt. If any shares of Common
      Stock, Options or Convertible Securities are issued to the owners of the non-surviving entity in connection with any merger in which the Company is the surviving entity, the amount of consideration therefor (for the purpose of determining the
      consideration paid for such Common Stock, Option or Convertible Security, but not for the purpose of the calculation of the Black Scholes Consideration Value) will be deemed to be the fair value of such portion of the net assets and business of the
      non-surviving entity as is attributable to such shares of Common Stock, Options or Convertible Securities (as the case may be). The fair value of any consideration other than cash or publicly traded securities will be determined jointly by the
      Company and the Holder. If such parties are unable to reach agreement within ten (10) days after the occurrence of an event requiring valuation (the “Valuation Event”), the fair value of such consideration will
      be determined within five (5) Trading Days after the tenth (10th) day following such Valuation Event by an independent, reputable appraiser jointly selected by the
      Company and the Holder. The determination of such appraiser shall be final and binding upon all parties absent manifest error and the fees and expenses of such appraiser shall be borne by the Company.  Notwithstanding anything to the contrary
      contained herein, if a calculation pursuant to this Section 2(a)(iv) would result in an Exercise Price that is lower than the par value of the Common Stock, then the Exercise Price shall be deemed to equal the par value of the Common Stock.

     

    
      (v)        Record Date.  If the Company takes a record of the holders of shares of Common Stock for the purpose of entitling them (A) to receive a dividend or other
        distribution payable in shares of Common Stock, Options or in Convertible Securities or (B) to subscribe for or purchase shares of Common Stock, Options or Convertible Securities, then such record date will be deemed to be the date of the issue or
        sale of the shares of Common Stock deemed to have been issued or sold upon the declaration of such dividend or the making of such other distribution or the date of the granting of such right of subscription or purchase, as the case may be.

    

     

    

    
      
        

    

    

    (vi)       No Readjustments. For the avoidance of doubt, in the event the Exercise Price has been adjusted pursuant to this Section 2(a) and the Dilutive Issuance
      that triggered such adjustment does not occur, is not consummated, is unwound or is cancelled after the facts for any reason whatsoever, in no event shall the Exercise Price be readjusted to the Exercise Price that would have been in effect if such
      Dilutive Issuance had not occurred or been consummated.]

     

    (b)  Voluntary Adjustment By Company.  The Company may at any time during the term of this Warrant, with the prior written consent of the Holder, (i) reduce the then current Exercise Price
      and/or (ii) increase the then current number of Warrant Shares, in each case, to any amount or number and for any period of time deemed appropriate by the Board of Directors of the Company.

     

    (c)  Adjustment Upon Subdivision or Combination of Common Stock.  If the Company at any time on or after the Closing Date subdivides (by any stock split, stock dividend, recapitalization or
      otherwise) one or more classes of its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect immediately prior to such subdivision will be proportionately reduced and the number of Warrant Shares will be
      proportionately increased.  If the Company at any time on or after the Closing Date combines (by combination, reverse stock split or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the
      Exercise Price in effect immediately prior to such combination will be proportionately increased and the number of Warrant Shares will be proportionately decreased.  Any adjustment under this Section 2(c) shall become effective at the close of
      business on the date the subdivision or combination becomes effective.

     

    
      (d)  Resets.  [INSERT IN SERIES A WARRANT: On each Reset Date the Exercise Price shall be adjusted to equal the applicable Reset Price.  Upon each
        Reset Date, the number of Warrant Shares issuable immediately prior to such reset shall be increased, but in no event decreased, to the number of shares of Common Stock determined by multiplying (x) the  Exercise Price in effect on the Issuance
        Date (as adjusted for stock splits, stock dividends, recapitalizations, reorganizations, reclassification, combinations, reverse stock splits or other similar events related to the Common Stock occurring after the Issuance Date), or if a Reset Date
        has occurred hereunder, the Reset Price in effect on the immediately preceding Reset Date (in each case, as adjusted for stock splits, stock dividends, recapitalizations, reorganizations, reclassification, combinations, reverse stock splits or
        other similar events related to the Common Stock occurring after such Reset Date), as applicable, by (y) the number of Warrant Shares acquirable upon exercise of this Warrant immediately prior to such reset (which number of Warrant Shares, for the
        avoidance of doubt, shall give effect to any prior exercises of this Warrant) without regard to any limitation on exercise included herein, and dividing the product thereof by the Exercise Price resulting from such reset.]  [INSERT IN SERIES B WARRANT: The Maximum Eligibility Number shall be increased (but not decreased) on each Reset Date to equal the applicable Reset Share Amount.]

       

        

    

    
      
        

    

    (e)  [INSERT IN SERIES A WARRANT: Other Events.  If any event occurs of the type contemplated by the provisions of this Section 2 but not expressly
      provided for by such provisions (including, without limitation, the granting of stock appreciation rights, phantom stock rights or other rights with equity features), then the Company’s Board of Directors will make an appropriate adjustment in the
      Exercise Price and the number of Warrant Shares, as mutually determined by the Company’s Board of Directors and the Required Holders, so as to protect the rights of the Holder; provided that no such adjustment pursuant to this Section 2(e)
      will increase the Exercise Price or decrease the number of Warrant Shares as otherwise determined pursuant to this Section 2.]

     

    3.       RIGHTS UPON DISTRIBUTION OF ASSETS.  If the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of
      Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property, Options, evidence of indebtedness or any other assets by way of a dividend, spin off,
      reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the Closing Date, then, in each such case, the Holder shall be entitled to
      participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations or
      restrictions on exercise of this Warrant, including without limitation, the Maximum Percentage) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of
      shares of Common Stock are to be determined for the participation in such Distribution (provided, however, that to the extent that the Holder’s right to participate in any such Distribution would result in the Holder and the other
      Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Distribution to such extent (and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such
      Distribution (and beneficial ownership) to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time or times as its right thereto would not result in the Holder and the other
      Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted such Distribution (and any Distributions declared or made on such initial Distribution or on any subsequent Distribution held similarly in
      abeyance) to the same extent as if there had been no such limitation).

     

    
      
        

    

    4.        PURCHASE RIGHTS; FUNDAMENTAL TRANSACTIONS.

     

    (a)  Purchase Rights.  In addition to any adjustments pursuant to Section 2 above, if at any time following the Closing Date the Company grants, issues or sells any Options, Convertible
      Securities or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire,
      upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any
      limitations or restrictions on exercise of this Warrant, including without limitation, the Maximum Percentage) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is
      taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that to the extent that the Holder’s right to participate in any
      such Purchase Right would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Purchase Right to such extent (and shall not be entitled to beneficial
      ownership of such shares of Common Stock as a result of such Purchase Right (and beneficial ownership) to such extent) and such Purchase Right to such extent shall be held in abeyance for the benefit of the Holder until such time or times as its
      right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted such right (and any Purchase Right granted, issued or sold on such initial Purchase
      Right or on any subsequent Purchase Right held similarly in abeyance) to the same extent as if there had been no such limitation).

     

    (b)  Fundamental Transactions.  The Company shall not enter into, allow or be a
        party to a Fundamental Transaction until the Reservation Date. If, at any time after the Reservation Date until this Warrant ceases to be outstanding, a Fundamental Transaction occurs or is consummated, then, upon any subsequent exercise of
      this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any
      limitation in Section 1(f) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental
      Transaction (without regard to any limitation in Section 1(f) on the exercise of this Warrant).  For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based
      on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the
      relative value of any different components of the Alternate Consideration.  If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same
      choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.  The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 4(b) pursuant to written agreements in form and substance
      reasonably satisfactory to the Required Holders and approved by the Required Holders (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a
      security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its Parent Entity)
      equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the
      exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of
      capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the
      Required Holders. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the
      “Company” shall be added to the term “Company” under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant

      referring to the “Company” shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly
        and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company in this Warrant.

     

    
      
        

    

    (c)  [INSERT IN SERIES A WARRANTS: Notwithstanding the foregoing, in the event of a Fundamental
      Transaction, at the request of the Holder delivered before the ninetieth (90th) day after the occurrence or consummation of such Fundamental Transaction, the Company (or
      the Successor Entity) shall purchase this Warrant from the Holder by paying to the Holder, within five (5) Business Days after such request (or, if later, on the effective date of the Fundamental Transaction), cash in an amount equal to the Black
      Scholes Value of the remaining unexercised portion of this Warrant on the effective date of such Fundamental Transaction; provided, however, that, if such Fundamental Transaction is not within the Company’s control, including not
      approved by the Company’s Board of Directors, the Holder shall only be entitled to receive from the Company or any Successor Entity, the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised
      portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with such Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the
      holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with such Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered
      or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such
      Fundamental Transaction.  The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within the later of (i) five (5) Business Days of the Holder’s election and (ii) the date of
      consummation of the Fundamental Transaction.]

     

    5.       NONCIRCUMVENTION.  The Company hereby covenants and agrees that the Company will not, by amendment of its Certificate of Incorporation or Bylaws, or through any reorganization,
      transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times
      in good faith carry out all of the provisions of this Warrant and take all action as may be required to protect the rights of the Holder.  Without limiting the generality of the foregoing, the Company (i) shall not increase the par value of any
      shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, (ii) shall take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and
      nonassessable shares of Common Stock upon the exercise of this Warrant, and (iii) shall, so long as any of the SPA Warrants are outstanding, take all action necessary to reserve and keep available out of its authorized and unissued shares of Common
      Stock, solely for the purpose of effecting the exercise of the SPA Warrants, the Required Reserve Amount of shares of Common Stock.

     

    
      
        

    

    6.        WARRANT HOLDER NOT DEEMED A STOCKHOLDER.  Except as otherwise specifically provided herein, the Holder, solely in such Person’s capacity as a holder of this Warrant, shall not be
      entitled to vote or receive dividends or be deemed the holder of capital stock of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person’s capacity as the Holder of this
      Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise),
      receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant.  In addition, nothing
      contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or
      by creditors of the Company.  Notwithstanding this Section 6, the Company shall provide the Holder with copies of the same notices and other information given to the stockholders of the Company generally, contemporaneously with the giving thereof to
      the stockholders.

     

    7.        REISSUANCE OF WARRANTS.

     

    (a)  Transfer of Warrant.  If this Warrant is to be transferred, the Holder shall surrender this Warrant to the Company, whereupon the Company will forthwith issue and deliver upon the order
      of the Holder a new Warrant (in accordance with Section 7(d)), registered as the Holder may request, representing the right to purchase the number of Warrant Shares being transferred by the Holder and, if less than the total number of Warrant Shares
      then underlying this Warrant is being transferred, a new Warrant (in accordance with Section 7(d)) to the Holder representing the right to purchase the number of Warrant Shares not being transferred.

     

    (b)  Lost, Stolen or Mutilated Warrant.  Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant, and, in
      the case of loss, theft or destruction, of any indemnification undertaking by the Holder to the Company in customary form and, in the case of mutilation, upon surrender and cancellation of this Warrant, the Company shall execute and deliver to the
      Holder a new Warrant (in accordance with Section 7(d)) representing the right to purchase the Warrant Shares then underlying this Warrant.

     

    (c)  Exchangeable for Multiple Warrants.  This Warrant is exchangeable, upon the surrender hereof by the Holder at the principal office of the Company, for a new Warrant or Warrants (in
      accordance with Section 7(d)) representing in the aggregate the right to purchase the number of Warrant Shares then underlying this Warrant, and each such new Warrant will represent the right to purchase such portion of such Warrant Shares as is
      designated by the Holder at the time of such surrender; provided, however, that no SPA Warrants for fractional Warrant Shares shall be given.

     

    
      
        

    

    (d)  Issuance of New Warrants.  Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant (i) shall be of like tenor with this Warrant,
      (ii) shall represent, as indicated on the face of such new Warrant, the right to purchase the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being issued pursuant to Section 7(a) or Section 7(c), the Warrant Shares
      designated by the Holder which, when added to the number of shares of Common Stock underlying the other new Warrants issued in connection with such issuance, does not exceed the number of Warrant Shares then underlying this Warrant), (iii) shall have
      an issuance date, as indicated on the face of such new Warrant which is the same as the Issuance Date, and (iv) shall have the same rights and conditions as this Warrant.

     

    8.        NOTICES.  Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall be given in accordance with Section 10(f) of the Securities
      Purchase Agreement.  The Company shall provide the Holder with prompt written notice of all actions taken pursuant to this Warrant, including in reasonable detail a description of such action and the reason therefor.  Without limiting the generality
      of the foregoing, the Company will give written notice to the Holder (i) immediately upon any adjustment of the Exercise Price, setting forth in reasonable detail, and certifying, the calculation of such adjustment and (ii) at least fifteen (15) days
      prior to the date on which the Company closes its books or takes a record (A) with respect to any dividend or distribution upon the shares of Common Stock, (B) with respect to any grants, issuances or sales of any Options, Convertible Securities or
      rights to purchase stock, warrants, securities or other property to holders of shares of Common Stock or (C) for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation; provided in each case that
      such information shall be made known to the public prior to or in conjunction with such notice being provided to the Holder.  It is expressly understood and agreed that the time of exercise specified by the Holder in each Exercise Notice shall be
      definitive and may not be disputed or challenged by the Company.

     

    9.        AMENDMENT AND WAIVER.  Except as otherwise provided herein, the provisions of this Warrant may be amended or waived and the Company may take any action herein prohibited, or omit to
      perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Required Holders. Any change, amendment or waiver pursuant to the immediately preceding sentence shall be binding on the Holder of this
      Warrant and all holders of the SPA Warrants.  [INSERT IN SERIES A WARRANTS: Notwithstanding the foregoing, after the date that is ten (10) Trading Days immediately following the Reservation Date, the
      provisions of this Warrant may be amended or waived and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, if the Company has obtained the written consent of the Holder.]

     

    
      
        

    

    10.      GOVERNING LAW; JURISDICTION; JURY TRIAL.  This Warrant shall be governed by and construed and enforced in accordance with, and all questions concerning the construction, validity,
      interpretation and performance of this Warrant shall be governed by, the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other
      jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. The Company hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York,
      Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding,
      any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.  The Company hereby
      irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to the Company at the address set forth in Section 10(f) of the Securities Purchase Agreement and
      agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.  Nothing contained herein
      shall be deemed or operate to preclude the Holder from bringing suit or taking other legal action against the Company in any other jurisdiction to collect on the Company’s obligations to the Holder, to realize on any collateral or any other security
      for such obligations, or to enforce a judgment or other court ruling in favor of the Holder.  THE COMPANY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE
        ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS WARRANT OR ANY TRANSACTION CONTEMPLATED HEREBY.

     

    11.      CONSTRUCTION; HEADINGS.  This Warrant shall be deemed to be jointly drafted by the Company and all the Buyers and shall not be construed against any Person as the drafter hereof. 
      The headings of this Warrant are for convenience of reference and shall not form part of, or affect the interpretation of, this Warrant.

     

    
      
        

    

    12.      DISPUTE RESOLUTION.  In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall cause the Transfer Agent to issue to the Holder the number of shares of Common Stock that is not disputed and the Company shall submit the disputed determinations or arithmetic calculations via
      facsimile or electronic mail within one (1) Business Day of receipt of the Exercise Notice giving rise to such dispute, as the case may be, to the Holder.  If the Holder and the Company are unable to agree upon such determination or calculation of
      the Exercise Price or the Warrant Shares within two (2) Business Days of such disputed determination or arithmetic calculation being submitted to the Holder, then the Company shall, within one (1) Business Day submit via facsimile or electronic mail
      (a) the disputed determination of the Exercise Price to an independent, reputable investment bank selected by the Holder and approved by the Company, such approval not to be unreasonably withheld, conditioned or delayed or (b) the disputed arithmetic
      calculation of the Warrant Shares to the Company’s independent, outside accountant.  The Company shall cause at its expense the investment bank or the accountant, as the case may be, to perform the determinations or calculations and notify the
      Company and the Holder of the results no later than five (5) Business Days from the time it receives the disputed determinations or calculations.  Such investment bank’s or accountant’s determination or calculation, as the case may be, shall be
      binding upon all parties absent demonstrable error.

     

    13.    REMEDIES, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF.  The remedies provided in this Warrant shall be cumulative and in addition to all other remedies available under this
      Warrant and the other Transaction Documents, at law or in equity (including a decree of specific performance and/or other injunctive relief).  No remedy contained herein shall be deemed a waiver of
        compliance with the provisions giving rise to such remedy. Nothing herein shall limit the right of the Holder to pursue actual damages for any failure by the Company to comply with the terms of this Warrant.  The Company acknowledges that a
      breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate.  The Company therefore agrees that, in the event of any such breach or threatened breach, the holder
      of this Warrant shall be entitled, in addition to all other available remedies, to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being required.

     

    14.     TRANSFER.  This Warrant and the Warrant Shares may be offered for sale, sold, transferred, pledged or assigned without the consent of the Company, except as may otherwise be required
      by Section 2(f) of the Securities Purchase Agreement.

     

    15.     SEVERABILITY.  If any provision of this Warrant is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that
      would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the
      remaining provisions of this Warrant so long as this Warrant as so modified continues to express, without material change, the original intentions of the Company and the Holder  as to the subject matter hereof and the prohibited nature, invalidity or
      unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the Company and the Holder  or the practical realization of the benefits that would otherwise be conferred upon
      the Company and the Holder.  The Company and the Holder will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the
      prohibited, invalid or unenforceable provision(s).

     

    
      
        

    

    16.     DISCLOSURE.  Upon receipt or delivery by the Company of any notice in accordance with the terms of this Warrant, unless the Company has in good faith determined that the matters
      relating to such notice do not constitute material, nonpublic information relating to the Company or its Subsidiaries, the Company shall contemporaneously with any such receipt or delivery publicly disclose such material, nonpublic information on a
      Current Report on Form 8-K or otherwise.  In the event that the Company believes that a notice contains material, nonpublic information relating to the Company or its Subsidiaries, the Company so shall indicate to the Holder contemporaneously with
      delivery of such notice, and in the absence of any such indication, the Holder shall be allowed to presume that all matters relating to such notice do not constitute material, nonpublic information relating to the Company or its Subsidiaries.

     

    17.     PAYMENT OF COLLECTION, ENFORCEMENT AND OTHER COSTS. If (a) this Warrant
        is placed in the hands of an attorney for collection or enforcement or is collected or enforced through any legal proceeding or the Holder otherwise takes action to collect amounts due under this Warrant or to enforce the provisions of this Warrant
        or (b) there occurs any bankruptcy, reorganization, receivership of the company or other proceedings affecting company creditors’ rights and involving a claim under this Warrant, then the Company shall pay the costs incurred by the Holder for such
        collection, enforcement or action or in connection with such bankruptcy, reorganization, receivership or other proceeding, including, without limitation, attorneys’ fees and disbursements.

     

    18.      CERTAIN DEFINITIONS.  For purposes of this Warrant, the following terms shall have the following meanings:

     

    (a)  “1933 Act” means the Securities Act of 1933, as amended.

     

    (b) [INSERT IN SERIES B WARRANT: “Additional Vested Common Shares” means the Exchange Shares issued in exchange for
      the Additional Common Shares (as defined in the Securities Purchase Agreement) delivered or deliverable to the initial Holder of this Warrant pursuant to the Securities Purchase Agreement without giving effect to any limitation on delivery to the
      Holder pursuant to Section 1(c)(iv) of the Securities Purchase Agreement.] [INSERT IN SERIES A WARRANT: Intentionally omitted.]

     

    (c) [INSERT IN SERIES A WARRANT: “Adjustment Right” means any right granted with respect to any securities issued in
      connection with, or with respect to, any issuance or sale (or deemed issuance or sale in accordance with Section 2(a)(i) or Section 2(a)(ii)) of shares of Common Stock (other than rights of the type described in Section 3 and 4 hereof) that could
      result in a decrease in the net consideration received by the Company in connection with, or with respect to, such securities (including, without limitation, any cash settlement rights, cash adjustment or other similar rights).] [INSERT IN SERIES B WARRANT: Intentionally omitted.]]

     

    
      
        

    

    (d) “Affiliate” shall have the meaning ascribed to such term in Rule 405 promulgated under the 1933 Act or any successor rule.

     

    (e)  [INSERT IN SERIES A WARRANT: “Approved Stock Plan” means any employee benefit plan or equity incentive plan
      which has been approved by the Board of Directors of the Company or a bona fide inducement grant to new employees outside of any such plan duly adopted by a majority of the non-employee members of the Board of Directors of the Company or a majority
      of the members of a committee of non-employee directors established for such purpose, pursuant to which the Company’s securities may be issued to any employee, officer, director or consultant for services provided to the Company.] [INSERT IN SERIES B WARRANT: Intentionally omitted.]

     

    (f)  “Attribution Parties” means, collectively, the following Persons: (i) any investment vehicle, including, any funds, feeder funds or managed accounts,
      currently, or from time to time after the Issuance Date, directly or indirectly managed or advised by the Holder’s investment manager or any of its Affiliates or principals, (ii) any direct or indirect Affiliates of the Holder or any of the
      foregoing, (iii) any Person acting or who could be deemed to be acting as a Group together with the Holder or any of the foregoing and (iv) any other Person whose beneficial ownership of the Common Stock would or could be aggregated with the Holder’s
      and the other Attribution Parties for purposes of Section 13(d) of the 1934 Act.  For clarity, the purpose of the foregoing is to subject collectively the Holder and all other Attribution Parties to the Maximum Percentage.

     

    (g) “Bid Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on an Eligible Market, the bid price of the Common Stock for the time in question (or the
        nearest preceding date) on the Eligible Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock is
        not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the Pink Open Market (f/k/a OTC Pink) published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its
        functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (c) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the
        Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

     

    
      
        

    

    (h) [INSERT IN SERIES A WARRANT: “Black Scholes Consideration Value” means the value of the applicable Option,
      Convertible Security or Adjustment Right (as the case may be) calculated using the Black-Scholes Option Pricing Model obtained from the “OV” function on Bloomberg determined as of the date of issuance and reflecting (i) a risk-free interest rate
      corresponding to the U.S. Treasury rate for a period equal to the remaining term of such Option, Convertible Security or Adjustment Right (as the case may be) as of the date of issuance of such Option, Convertible Security or Adjustment Right (as the
      case may be), (ii) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately following the public announcement of the issuance of such Option,
      Convertible Security or Adjustment Right (as the case may be), or, if the issuance of such Option, Convertible Security or Adjustment Right (as the case may be) is not publicly announced, the date of issuance of such Option, Convertible Security or
      Adjustment Right (as the case may be), (iii) the underlying price per share used in such calculation shall be the highest Weighted Average Price of the Common Stock during the period beginning on the Trading Day prior to the execution of definitive
      documentation relating to the issuance of such Option or Convertible Security (as the case may be) and ending on (A) the Trading Day immediately following the public announcement of the execution of definitive documents with respect to the issuance
      of such Option or Convertible Security (as the case may be), or, (B) if the execution of definitive documents with respect to the issuance of such Option or Convertible Security (as the case may be) is not publicly announced, the date of such
      issuance, (iv) a remaining option time equal to the time between the date of the public announcement of the execution of definitive documents with respect to the issuance of such Option or Convertible Security (as the case may be) or, if the
      execution of definitive documents with respect to the issuance of such Option or Convertible Security (as the case may be) is not publicly announced, the date of such issuance, (v) a zero cost of borrow and (vi) a 365 day annualization factor.] [INSERT IN SERIES B WARRANT: Intentionally omitted.]

     

    (i)  [INSERT IN SERIES A WARRANT: “Black Scholes Value” means the value of this Warrant calculated using the
      Black-Scholes Option Pricing Model obtained from the “OV” function on Bloomberg determined as of the day immediately following the public announcement of the applicable contemplated Fundamental Transaction, or, if such contemplated Fundamental
      Transaction is not publicly announced, the date such Fundamental Transaction has occurred or is consummated, for pricing purposes and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining
      term of this Warrant as of such date of request, (ii) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately following the public announcement of
      the applicable contemplated Fundamental Transaction, or, if such contemplated Fundamental Transaction is not publicly announced, the date such Fundamental Transaction has occurred or is consummated, (iii) the underlying price per share used in such
      calculation shall be the greater of (x) the highest Weighted Average Price of the Common Stock during the period beginning on the Trading Day prior to the execution of definitive documentation relating to the applicable Fundamental Transaction and
      ending on (A) the Trading Day immediately following the public announcement of such contemplated Fundamental Transaction, if the applicable contemplated Fundamental Transaction is publicly announced or (B) the Trading Day immediately following the
      consummation of the applicable Fundamental Transaction if the applicable contemplated Fundamental Transaction is not publicly announced and (y) the sum of the price per share being offered in cash, if any, plus the value of any non-cash
      consideration, if any, being offered in such Fundamental Transaction, (iv) a remaining option time equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction or, if such applicable
      contemplated Fundamental Transaction is not publicly announced, the date such Fundamental Transaction has occurred or is consummated, (v) a zero cost of borrow and (vi) a 365 day annualization factor.] [INSERT IN
        SERIES B WARRANT: Intentionally omitted.]

     

    (j)  “Bloomberg” means Bloomberg Financial Markets.

     

    
      
        

    

    (k)  “Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law
      to remain closed.

     

    (l)  “Closing Date” shall have the meaning ascribed to such term in the Securities Purchase Agreement.

     

    (m) “Common Stock” means (i) the Company’s shares of common stock, par value $0.0001 per share, and (ii) any capital stock into which such Common Stock shall
      have been changed or any capital stock resulting from a reclassification, reorganization or recapitalization of such Common Stock.

     

    (n)  “Convertible Securities” means any stock or securities (other than Options) directly or indirectly convertible into or exercisable or exchangeable for
      shares of Common Stock.

     

    (o) “Designee” means Altium Capital Management, LP.

     

    (p) “Eligible Market” means the Principal Market, the NYSE American, The Nasdaq Global Select Market, The Nasdaq Global Market or The New York Stock Exchange,
      Inc.

     

    (q)  [INSERT IN SERIES A WARRANT: Intentionally omitted.][INSERT IN SERIES B WARRANT: “End Reset Date” means the forty-fifth (45th) Trading Day immediately following each End Reset Measuring Date.]

     

    (f)  [INSERT IN SERIES B WARRANT: “End Reset Measuring Date” each of the following:

     

    (1)   each date on which a Registration Statement registering any Registrable Securities for resale by the Holder is declared effective by the SEC and/or is available for use;

     

    (2)   if there is no effective Registration Statement(s) that is available for use registering all of the Underlying Securities for resale by the Holder on the earlier to occur of (x) the Rule 144
      Date and (y) [•]5 (such earlier date, the “Six Month Reset Date”) then, the Six Month Reset Date; and

     

     (3)   if a Public Information Failure has occurred at any time following the Six Month Reset Date, the earlier to occur of (x) the date that such Public Information Failure is cured and no longer prevents the Holder
      from selling all Underlying Securities pursuant to Rule 144 without restriction or limitation and (y) the earlier to occur of (I) the date the Holder can sell all Underlying Securities pursuant to Rule 144 without restriction or limitation and
      without the requirement to be in compliance with Rule 144(c)(1) and (II) [•]6.]

     

    

    
      
 

    5 Insert the date that is six (6) months immediately following the Issuance Date.

     
      6 Insert the date that is the one (1) year anniversary of the Issuance Date.

       

      

    

    
      
        

    

    

    (r)  [INSERT IN SERIES A WARRANT: “Excluded Securities” means any Common Stock issued or issuable or deemed to be
      issued in accordance with Section 2(a)(i) or Section 2(a)(ii) by the Company (including, for the avoidance of doubt, Options or Convertible Securities issued by the Company): (i) under any Approved Stock Plan; provided, however, that
      no more than an aggregate of [•]7 shares of Common Stock (as adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction
      occurring relating to the Common Stock after the Warrant Closing Date (as defined in the Securities Purchase Agreement)) are issued or issuable to consultants and/or to new employees outside of an employee benefit plan or equity incentive plan
      hereunder as Excluded Securities, (ii) upon exercise of any SPA Warrants and any Series B Warrants issued pursuant to the Securities Purchase Agreement; provided, that the terms of such SPA Warrants and Series B Warrants are not amended,
      modified or changed on or after the Subscription Date, (iii) upon conversion, exercise or exchange of any Options or Convertible Securities which are outstanding on the day immediately preceding the Subscription Date; provided, that such
      issuance of Common Stock upon exercise of such Options or Convertible Securities is made pursuant to the terms of such Options or Convertible Securities in effect on the date immediately preceding the Subscription Date and such Options or Convertible
      Securities are not amended, modified or changed on or after the Subscription Date, except as set forth in the Executed Merger Agreement, (iv) prior to the Closing Date in connection with the exercise, exchange, cancellation, modification or
      termination of Parent Warrants (as defined in the Draft Merger Agreement (as defined in the Securities Purchase Agreement)) that are outstanding on the day immediately preceding the Subscription Date, (v) pursuant to the Executed Merger Agreement or
      the Final Form S-4 (as defined in the Securities Purchase Agreement), (vi) in connection with acquisitions, asset purchases, licenses, joint ventures, technology license agreements, collaborations or strategic transactions involving the Company and
      other Persons approved by the Board of Directors of the Company but only if such Person is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide
      to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing
      in securities or (vii) to financial institutions or lessors in connection with credit or lending arrangements, equipment financings or lease arrangements in an amount not to exceed an aggregate of [•]8 shares of Common Stock (as adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction occurring relating to the Common Stock after the Warrant Closing Date).] [INSERT IN SERIES B WARRANT: Intentionally omitted.]

     

    
      (s)   “Expiration Date” means [INSERT IN SERIES A WARRANTS: the date sixty (60) months after the Issuance Date or,
        if such date falls on a day other than a Business Day or on which trading does not take place on the Principal Market (a “Holiday”), the next day that is not a Holiday]
          [INSERT IN SERIES B WARRANTS: the day following the later to occur of (x) the Reservation Date and (y) the date on which this Warrant has been exercised in full and no Warrant Shares remain issuable hereunder (without giving effect any
        limitation on exercise included herein)].

    

     

    

    
      
 

    7 Insert three percent (3.0%) of the issued and outstanding shares of Common Stock determined as of the Warrant Closing Date.

     

    8 Insert three percent (3.0%) of the issued and outstanding shares of Common Stock determined as of the Warrant Closing Date.

     

    
      
        

    

    (t)   [INSERT IN SERIES B WARRANT: “Exchange Shares” shall have the meaning ascribed to such term in the Securities Purchase Agreement.] [INSERT IN SERIES A WARRANT: Intentionally omitted.]

     

    (u)   “Executed Merger Agreement” shall have the meaning ascribed to such term in the Securities Purchase Agreement.

     

    (v)  “Fundamental Transaction” means (A) that the Company shall, directly or indirectly, including through Subsidiaries, Affiliates or otherwise, in one or
      more related transactions, (i) consolidate or merge with or into (whether or not the Company is the surviving corporation) another Subject Entity, or (ii) sell, assign, transfer, convey or otherwise dispose of all or substantially all of the
      properties or assets of the Company or any of its “significant subsidiaries” (as defined in Rule 1-02 of Regulation S-X) to one or more Subject Entities, or (iii) make, or allow one or more Subject Entities to make, or allow the Company to be subject
      to or have its Common Stock be subject to or party to one or more Subject Entities making, a purchase, tender or exchange offer that is accepted by the holders of at least either (x) 50% of the outstanding shares of Common Stock, (y) 50% of the
      outstanding shares of Common Stock calculated as if any shares of Common Stock held by all Subject Entities making or party to, or Affiliated with any Subject Entities making or party to, such purchase, tender or exchange offer were not outstanding;
      or (z) such number of shares of Common Stock such that all Subject Entities making or party to, or Affiliated with any Subject Entity making or party to, such purchase, tender or exchange offer, become collectively the beneficial owners (as defined
      in Rule 13d-3 under the 1934 Act) of at least 50% of the outstanding shares of Common Stock, or (iv) consummate a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or
      scheme of arrangement) with one or more Subject Entities whereby all such Subject Entities, individually or in the aggregate, acquire, either (x) at least 50% of the outstanding shares of Common Stock, (y) at least 50% of the outstanding shares of
      Common Stock calculated as if any shares of Common Stock held by all the Subject Entities making or party to, or Affiliated with any Subject Entity making or party to, such stock purchase agreement or other business combination were not outstanding;
      or (z) such number of shares of Common Stock such that the Subject Entities become collectively the beneficial owners (as defined in Rule 13d-3 under the 1934 Act) of at least 50% of the outstanding shares of Common Stock, or (v) reorganize,
      recapitalize or reclassify its Common Stock, (B) that the Company shall, directly or indirectly, including through Subsidiaries, Affiliates or otherwise, in one or more related transactions, allow any Subject Entity individually or the Subject
      Entities in the aggregate to be or become the “beneficial owner” (as defined in Rule 13d-3 under the 1934 Act), directly or indirectly, whether through acquisition, purchase, assignment, conveyance, tender, tender offer, exchange, reduction in
      outstanding shares of Common Stock, merger, consolidation, business combination, reorganization, recapitalization, spin-off, scheme of arrangement, reorganization, recapitalization or reclassification or otherwise in any manner whatsoever, of either
      (x) at least 50% of the aggregate ordinary voting power represented by issued and outstanding shares of Common Stock, (y) at least 50% of the aggregate ordinary voting power represented by issued and outstanding shares of Common Stock not held by all
      such Subject Entities as of the Subscription Date calculated as if any shares of Common Stock held by all such Subject Entities were not outstanding, or (z) a percentage of the aggregate ordinary voting power represented by issued and outstanding
      shares of Common Stock or other equity securities of the Company sufficient to allow such Subject Entities to effect a statutory short form merger or other transaction requiring other stockholders of the Company to surrender their shares of Common
      Stock without approval of the stockholders of the Company or (C) that the Company shall, directly or indirectly, including through Subsidiaries, Affiliates or otherwise, in one or more related transactions, the issuance of or the entering into any
      other instrument or transaction structured in a manner to circumvent, or that circumvents, the intent of this definition in which case this definition shall be construed and implemented in a manner otherwise than in strict conformity with the terms
      of this definition to the extent necessary to correct this definition or any portion of this definition which may be defective or inconsistent with the intended treatment of such instrument or transaction. For the avoidance of doubt, in no event
      shall the Merger (as defined in the Executed Merger Agreement) or the transactions contemplated by the Executed Merger Agreement and completed before the Issuance Date be deemed to be a “Fundamental Transaction.”

     

    
      
        

    

    (w) “Group” means a “group” as that term is used in Section 13(d) of the 1934 Act and as defined in Rule 13d-5 thereunder.

     

    (x) [INSERT IN SERIES B WARRANT: “Initial Common Shares” means the Exchange Shares issued in exchange for the Initial
      Common Shares (as defined in the Securities Purchase Agreement) purchased by the initial Holder of this Warrant.] [INSERT IN SERIES A WARRANT: Intentionally omitted.]

     

    (y) [INSERT IN SERIES B WARRANT: “Initial Maximum Eligibility Number” means, the number (if positive) obtained by
      subtracting (i) the sum of (x) the number of Initial Common Shares purchased by the initial Holder of this Warrant on the Closing Date (as adjusted for stock splits, stock dividends, recapitalizations, reorganizations, reclassification, combinations,
      reverse stock splits or other similar events related to the Common Stock occurring after the Closing Date) and (y) the number of Additional Vested Common Shares (as adjusted for stock splits, stock dividends, recapitalizations, reorganizations,
      reclassification, combinations, reverse stock splits or other similar events related to the Common Stock occurring after the applicable date the Additional Vested Common Shares are delivered) delivered or deliverable to the initial Holder of this
      Warrant pursuant to the Securities Purchase Agreement, from (ii) the quotient determined by dividing (x) the aggregate Purchase Price paid by the initial Holder of this Warrant on the Closing Date, by (y) the greater of (I) the Reset Floor Price and
      (II) eighty-five percent (85%) of the sum of the five (5) lowest Weighted Average Prices of the Common Stock during the period beginning on the first (1st) Trading Day
      immediately following the Closing Date and ending on the First Additional Exchange Shares Delivery Date (as defined in the Securities Purchase Agreement), inclusive (as adjusted for stock splits, stock dividends, recapitalizations, reorganizations,
      reclassification, combinations, reverse stock splits or other similar events during such period) (as adjusted for stock splits, stock dividends, recapitalizations, reorganizations, reclassification, combinations, reverse stock splits or other similar
      events related to the Common Stock occurring after the Closing Date), divided by five (5).] [INSERT IN SERIES A WARRANT: Intentionally omitted.]

     

    
      
        

    

    (z)  [INSERT IN SERIES B WARRANT: “Interim Reset Date” means each of the ninth (9th) Trading Day, the eighteenth
      (18th) Trading Day, the twenty-seventh (27th) Trading Day and the thirty-sixth (36th) Trading Day, in each case, immediately following each End Reset Measuring Date.] [INSERT IN SERIES A WARRANT: Intentionally
      omitted.]

     

    (aa)  [INSERT IN SERIES B WARRANT: “Maximum Eligibility Number” means, initially, the Initial Maximum Eligibility
      Number, and such number shall be increased (but not decreased) on each Reset Date to equal the applicable Reset Share Amount.] [INSERT IN SERIES A WARRANT: Intentionally
      omitted.]

     

    (bb)  “Options” means any rights, warrants or options to subscribe for or purchase (i) shares of Common Stock or (ii) Convertible Securities, including
      without limitation, the Warrants (as defined in the Securities Purchase Agreement).

     

    (cc)  “Parent Entity” of a Person means an entity that, directly or indirectly, controls the applicable Person, including such entity whose common capital or
      equivalent equity security is quoted or listed on an Eligible Market (or, if so elected by the Holder, any other market, exchange or quotation system), or, if there is more than one such Person or such entity, the Person or such entity designated by
      the Required Holders or in the absence of such designation, such Person or entity with the largest public market capitalization as of the date of consummation of the Fundamental Transaction.

     

    (dd)  “Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any
      other entity and a government or any department or agency thereof.

     

    (ee)  “Principal Market” means The Nasdaq Capital Market.

     

    (ff)  [INSERT IN SERIES B WARRANT:  “Public Information Failure” shall have the meaning ascribed to such term in the
      Securities Purchase Agreement.] [INSERT IN SERIES A WARRANT: Intentionally omitted.]

     

    (gg)  [INSERT IN SERIES B WARRANT: “Purchase Price” shall have the meaning ascribed to such term in the Securities
      Purchase Agreement.] [INSERT IN SERIES A WARRANT: Intentionally omitted.]

     

    (hh)  “Registrable Securities” shall have the meaning ascribed to such term in the Registration Rights Agreement.

     

    (ii)  “Registration Rights Agreement” means that certain Registration Rights Agreement dated as of the Subscription Date by and among the Company and the
      Buyers.

     

    (jj)  “Registration Statement” shall have the meaning ascribed to such term in the Registration Rights Agreement.

     

    (kk) “Required Holders” means the holders of the SPA Warrants representing at least a majority of the shares of Common Stock underlying the SPA Warrants then
      outstanding and shall include the Designee so long as the Designee or any of its Affiliates holds any SPA Warrants.

     

    
      
        

    

    (ll)         “Reservation Date” means the forty-fifth (45th) Trading Day immediately following the earlier to occur of (x) the date the Holder can sell all
      Underlying Securities pursuant to Rule 144 without restriction or limitation and without the requirement to be in compliance with Rule 144(c)(1) and (y) [•]9.

     

    (mm) “Reset Date” [INSERT IN SERIES A WARRANT: shall have the meaning ascribed to such term in the Series B Warrants.] [INSERT IN SERIES B WARRANT: means each Interim Reset Date and each End Reset Date; provided, however, that the Holder may by written notice to the Company
      elect to waive any such Reset Date; provided, further, that any Reset Date that has been waived pursuant to the immediately preceding proviso may be advanced or delayed to any date selected by the Holder; provided, further,
      that each End Reset Date may be advanced, but not delayed.]

     

    (nn) “Reset Floor Price” means $[•]10 (as adjusted for stock splits, stock
      dividends, recapitalizations, reorganizations, reclassification, combinations, reverse stock splits or other similar events related to the Common Stock occurring after the Closing Date).

     

    (oo)  [INSERT IN SERIES B WARRANT: “Reset Period” means the period beginning on the End Reset Measuring Date and
      ending on the applicable Reset Date.] [INSERT IN SERIES A WARRANT: Intentionally omitted.]

     

    (pp)  “Reset Price” means [INSERT IN SERIES B WARRANT: the arithmetic average of the five (5) lowest Weighted Average
      Prices of the Common Stock during the applicable Reset Period immediately preceding the applicable Reset Date (as adjusted for stock splits, stock dividends, recapitalizations, reorganizations, reclassification, combinations, reverse stock splits or
      other similar events during such period); provided, however, that the Reset Price shall not be lower than the Reset Floor Price]. [INSERT IN SERIES A WARRANT: the lower of (i) the Exercise Price
      then in effect and (ii) 120% of the applicable Reset Price (as defined in the Series B Warrants) determined as of the related Reset Date.]

     

    
      (qq)  [INSERT IN SERIES B WARRANT: “Reset Share Amount” means the number of shares of Common Stock equal to the
        number (if positive) obtained by subtracting (I) the sum of (i) the number of Initial Common Shares purchased by the initial Holder of this Warrant pursuant to the Securities Purchase Agreement (as adjusted for stock splits, stock dividends,
        recapitalizations, reorganizations, reclassification, combinations, reverse stock splits or other similar events related to the Common Stock occurring after the Subscription Date) and (ii) the number of Additional Vested Common Shares (as adjusted
        for stock splits, stock dividends, recapitalizations, reorganizations, reclassification, combinations, reverse stock splits or other similar events related to the Common Stock occurring after the applicable date the Additional Vested Common Shares
        are delivered) delivered or deliverable to the initial Holder of this Warrant pursuant to the Securities Purchase Agreement, from (II) the quotient determined by dividing (x) the aggregate Purchase Price paid by the initial Holder of this Warrant
        pursuant to the Securities Purchase Agreement, by (y) the applicable Reset Price determined as of the related Reset Date.] [INSERT IN SERIES A WARRANT: Intentionally
        omitted.]

    

     

    

    
      
 

    9 Insert the date that is the one (1) year anniversary of the Issuance Date.

     

    10 Insert price equal to: $10,000,000 divided by the Parent Fully Diluted Number (as defined in the Securities Purchase Agreement),
      calculated solely for this purpose by limiting the amount of any Additional Vested Common Shares up to a cap equal to the number of Initial Common Shares, without giving effect to the limitations under Section 1(c)(iv) of the Securities Purchase
      Agreement, rounded to four decimal places.

     

    
      
        

    

    (rr)  “Rule 144” means Rule 144 promulgated under the 1933 Act or any successor rule.

     

    (ss) [INSERT IN SERIES B WARRANT: “Rule 144 Date” means the first date on which the Holder can sell all the
      Underlying Securities without restriction or limitation pursuant to Rule 144.] [INSERT IN SERIES A WARRANT: Intentionally omitted.]

     

    (tt)  [INSERT IN SERIES B WARRANT:  “Series A Warrants” shall have the meaning ascribed to such term in the
      Securities Purchase Agreement.] [INSERT IN SERIES A WARRANT: “Series B Warrants” shall have the meaning ascribed to such term in the Securities Purchase Agreement.]

     

    (uu)  “Share Delivery Date” means the earlier of (i) the second (2nd) Trading
      Day and (ii) the number of Trading Days comprising the Standard Settlement Period, in each case, following the date on which the Holder delivers the applicable Exercise Notice to the Company, so long as the Holder delivers the applicable Aggregate
      Exercise Price (or notice of a Cashless Exercise) on or prior to the earlier of (i) the second (2nd) Trading Day following the date on which the Holder has delivered the
      applicable Exercise Notice to the Company and (ii) the number of Trading Days comprising the Standard Settlement Period following the date on which the Holder has delivered the applicable Exercise Notice to the Company (provided that if the
      applicable Aggregate Exercise Price (or applicable notice of a Cashless Exercise) has not been delivered by such date, the applicable Share Delivery Date shall be one (1) Trading Day after the Holder has delivered the applicable Aggregate Exercise
      Price (or applicable notice of a Cashless Exercise to the Company).

     

    (vv)  “Standard Settlement Period” means the standard settlement period, expressed in a number of Trading Days, on the Company’s primary Eligible Market with
      respect to the Common Stock as in effect on the date of delivery of the applicable Exercise Notice.

     

    (ww)  “Subject Entity” means any Person, Persons or Group or any Affiliate or associate of any such Person, Persons or Group.

     

    (xx)  “Subsidiary” shall have the meaning ascribed to such term in the Securities Purchase Agreement.

     

    (yy)  “Successor Entity” means one or more Person or Persons (or, if so elected by the Holder, the Company or Parent Entity) formed by, resulting from or
      surviving any Fundamental Transaction or one or more Person or Persons (or, if so elected by the Holder, the Company or the Parent Entity) with which such Fundamental Transaction shall have been entered into.

     

    
      
        

    

    (zz)  “Trading Day” means any day on which the Common Stock is traded on the Principal Market, or, if the Principal Market is not the principal trading market
      for the Common Stock on such day, then on the principal securities exchange or securities market on which the Common Stock is then traded.

     

    (aaa) [INSERT IN SERIES B WARRANT: “Underlying Securities” means (i) the shares of Common Stock issued or issuable
      upon exercise of the Series A Warrants, (ii) the shares of Common Stock issued or issuable upon exercise of the SPA Warrants and (iii) any capital stock of the Company issued or issuable with respect to the Series A Warrants, the SPA Warrants or the
      shares of Common Stock issued or issuable upon exercise of the Series A Warrants or the SPA Warrants, in each case as a result of any stock split, stock dividend, recapitalization, exchange or similar event or otherwise, without regard to any
      limitations on the exercise of the Series A Warrants or the SPA Warrants.] [INSERT IN SERIES A WARRANT: Intentionally omitted.]

     

    (bbb)  “Weighted Average Price” means, for any security as of any date, the dollar volume-weighted average price for such security on the Principal Market
      during the period beginning at 9:30:00 a.m., New York time (or such other time as the Principal Market publicly announces is the official open of trading), and ending at 4:00:00 p.m., New York time (or such other time as the Principal Market publicly
      announces is the official close of trading), as reported by Bloomberg through its “Volume at Price” function or, if the foregoing does not apply, the dollar volume-weighted average price of such security in the over-the-counter market on the
      electronic bulletin board for such security during the period beginning at 9:30:00 a.m., New York time (or such other time as such market publicly announces is the official open of trading), and ending at 4:00:00 p.m., New York time (or such other
      time as such market publicly announces is the official close of trading), as reported by Bloomberg, or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the average of the highest closing bid price
      and the lowest closing ask price of any of the market makers for such security as reported in the OTC Link or Pink Open Market (f/k/a OTC Pink) published by the OTC Markets Group, Inc. (or similar
        organization or agency succeeding to its functions of reporting prices). If the Weighted Average Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Weighted Average Price of such security on
      such date shall be the fair market value as mutually determined by the Company and the Holder.  If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved pursuant to Section 12
      with the term “Weighted Average Price” being substituted for the term “Exercise Price.” All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or other similar transaction
      relating to the Common Stock during the applicable calculation period.

     

    [Signature Page Follows]

    

    

    
      
        

    

    IN WITNESS WHEREOF, the Company has caused this Warrant to Purchase Common Stock to be duly
        executed as of the Issuance Date set out above.

    

    

    	 	
            OCUPHIRE PHARMA, INC.

          
	 	

          

    	 	
            By:

          	 	 

    	 	
            Name:

          
	 	
            Title:

          

     

    

    
      
        

    

    EXHIBIT A

    

    

    EXERCISE NOTICE

    TO BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS

    WARRANT TO PURCHASE COMMON STOCK

    

    

    OCUPHIRE PHARMA, INC.

     

    

    
      The undersigned holder hereby exercises the right to purchase _________________ shares of Common Stock (“Warrant Shares”) of Ocuphire
        Pharma, Inc., a Delaware corporation formerly known as Rexahn Pharmaceuticals, Inc. (the “Company”), evidenced by the attached Warrant to Purchase Common Stock (the “Warrant”).

        [INSERT IN SERIES B WARRANT: In lieu of a fixed number of Warrant Shares, the undersigned holder may elect to indicate above a percentage of the trading volume on the date of this Exercise Notice, which may
        be subject to a minimum and/or a maximum number of Warrant Shares, all subject to the provisions of Section 1(f) of the Warrant. If a fixed number of Warrant Shares is not indicated above, then the number of Warrant Shares and the Aggregate
        Exercise Price set forth in Sections 1, 2 and 3 of this Exercise Notice shall be mutually calculated by the Company and the undersigned holder after the end of trading on the Principal Market on the date of this Exercise Notice in accordance with
        the foregoing instructions and the provisions of Section 1(f) of the Warrant.] Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Warrant.

    

     

    

    1.  Form of Exercise Price.  The Holder intends that payment of the Exercise Price shall be made as:

    

    

    
      	
               

            	

            	
              a “Cash Exercise” with respect to _________________ Warrant Shares; and/or

            
	
               

            	
               

            	
               

            
	
               

            	

            	
              a “Cashless Exercise” with respect to _______________ Warrant Shares, resulting in a delivery obligation of the Company to the Holder of __________ shares of Common Stock representing the applicable Net Number.

            
	 

    

    

    

    2.  Payment of Exercise Price.  In the event that the holder has elected a Cash Exercise with respect to some or all of the Warrant Shares to be issued pursuant hereto, the holder shall pay the
      Aggregate Exercise Price in the sum of $___________________ to the Company in accordance with the terms of the Warrant.

    

    

    3.  Delivery of Warrant Shares.  The Company shall deliver to the holder __________ Warrant Shares in accordance with the terms of the Warrant.

    

    

    4. Please issue the Common Stock into which the Warrant is being exercised to the Holder, or for its benefit, as follows:

    

    

    
      ☐        Check here if requesting delivery as a certificate to the following name and to the following address:

    

     

    

    
      
        

    

    	
            Issue to:

          	

          	 

    	 	

          	 

    	
            Address:

          	 	 

    	
            Telephone Number:

          	

          	 

    	
            Facsimile Number:

          	

          	 

    

    

    	☐	
            Check here if requesting delivery by Deposit/Withdrawal at Custodian as follows:

          

    

    

    	
            DTC Participant:

          	

          	 

    	
            DTC Number:

          	

          	 

    

    

    	
            Account Number:

          	 	 
	 	 	 
	
            Authorization:

          	 	 

    

    

    	
            By:

          	

          	 

    	
            Title:

          	

          	 

    	
            Dated:

          	 

    Account Number (if electronic book entry transfer):          

    
      	
              Transaction Code Number (if electronic book entry transfer):

            	

            	
               

            

    

     

    

    Date: _______________ __, ______

     

    

    
      	

            	 

    

       Name of Registered Holder

    

    

    	
            By:

          	

          	 

    	 	
            Name:

          
	 	
            Title:

          

    

    

    
      
        

    

    ACKNOWLEDGMENT

    

    

    The Company hereby acknowledges this Exercise Notice and hereby directs [Olde Monmouth Stock Transfer Co., Inc.] to issue the above indicated number of shares of Common Stock in accordance with the
      Transfer Agent Instructions dated [●], 2020 from the Company and acknowledged and agreed to by [Olde Monmouth Stock Transfer Co., Inc.].

    

    

    	 	
            OCUPHIRE PHARMA, INC.

          
	 	

          

    	 	
            By:

          	

          	 

    	 	
            Name:

          
	 	
            Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]